These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30229926)

  • 1. Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis.
    Li X; Roy A; Murthy B
    J Clin Pharmacol; 2019 Feb; 59(2):245-257. PubMed ID: 30229926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
    Gandhi Y; Passarell JA; Roy A; Murthy B
    J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
    D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G
    Clin Rheumatol; 2017 Dec; 36(12):2655-2665. PubMed ID: 28822046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients.
    Hasegawa M; Imai Y; Hiraoka M; Ito K; Roy A
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):803-32. PubMed ID: 22002809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
    Genovese MC; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Porawska W; Box J; Legerton C; Nasonov E; Durez P; Aranda R; Pappu R; Delaet I; Teng J; Alten R
    Arthritis Rheum; 2011 Oct; 63(10):2854-64. PubMed ID: 21618201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
    Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
    Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
    Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Berman A; Calvo Penadés I; Antón J; Ávila-Zapata F; Cuttica R; Horneff G; Foeldvari I; Keltsev V; Kingsbury DJ; Viola DO; Joos R; Lauwerys B; Paz Gastañaga ME; Rama ME; Wouters C; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Miraval T; Ally MMTM; Rubio-Pérez N; Solau Gervais E; van Zyl R; Li X; Nys M; Wong R; Banerjee S; Lovell DJ; Martini A; Ruperto N;
    Arthritis Rheumatol; 2018 Jul; 70(7):1144-1154. PubMed ID: 29481737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
    Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
    Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
    Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H
    Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
    Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
    Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
    Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
    Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
    J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
    Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
    Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach.
    Lon HK; Liu D; DuBois DC; Almon RR; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2013 Dec; 40(6):701-12. PubMed ID: 24233383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
    Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
    J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.
    Roy A; Mould DR; Wang XF; Tay L; Raymond R; Pfister M
    J Clin Pharmacol; 2007 Nov; 47(11):1408-20. PubMed ID: 17962428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
    Genovese MC; Pacheco-Tena C; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente RM; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Elegbe A; Wong R; Li X; Banerjee S; Alten R
    J Rheumatol; 2018 Aug; 45(8):1085-1092. PubMed ID: 29657147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
    Ternant D; Ducourau E; Fuzibet P; Vignault C; Watier H; Lequerré T; Le Loët X; Vittecoq O; Goupille P; Mulleman D; Paintaud G
    Br J Clin Pharmacol; 2015 Feb; 79(2):286-97. PubMed ID: 25223394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.